DMD Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 28, 2008; DOI: 10.1124/dmd.108.022285


0090-9556/08/3612-2492-2498$20.00
DMD 36:2492-2498, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.022285v1
36/12/2492    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Garver, E.
Right arrow Articles by Han, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garver, E.
Right arrow Articles by Han, C.

Involvement of Intestinal Uptake Transporters in the Absorption of Azithromycin and Clarithromycin in the Rat

Eric Garver, Erin D. Hugger, Shawn P. Shearn, Anuradha Rao, Paul A. Dawson, Charles B. Davis, and Chao Han

Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Collegeville, Pennsylvania (E.G., E.D.H., S.P.S., C.B.D., C.H.); and Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina (A.R., P.A.D.)

Macrolide antibiotics azithromycin (AZI) and clarithromycin (CLARI) are large molecular weight compounds and are substrates for apically polarized efflux transporters such as P-glycoprotein, which can potentially restrict intestinal absorption. However, despite these undesired physicochemical and biopharmaceutical properties, AZI and CLARI exhibit moderate to excellent p.o. bioavailability in preclinical species and humans. Intestinal uptake transporters, such as organic anion transporting polypeptides (OATPs), can facilitate the uptake of drugs that are substrates and hence increase p.o. absorption. The present study was designed to determine whether the intestinal Oatps are involved in absorption of these macrolides. AZI or CLARI was dosed p.o. to Sprague-Dawley rats after p.o. administration with vehicle or rifamycin SV (RIF), an OATP inhibitor. The p.o. exposures of AZI and CLARI were reduced 65 and 45%, respectively, when coadministered with an optimized RIF regimen. The p.o. RIF had no affect on the total blood clearance of these macrolides and most likely did not cause induction of metabolizing enzymes and/or transporters. Therefore, the results suggest that inhibition of an RIF-sensitive uptake transporter such as Oatp along the rat gastrointestinal tract was responsible for reduced p.o. exposure of AZI and CLARI. In addition, AZI and CLARI caused inhibition of taurocholate uptake in rat Oatp1a5-transfected Madin-Darby canine kidney cell monolayers. The in vitro and in vivo results suggest that the intestinal Oatps are involved in the p.o. absorption of AZI and CLARI in the rat.


Address correspondence to: Dr. Eric Garver, Oncology Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, 1250 South Collegeville Road, UP1235, Collegeville, PA 19426. E-mail: eric.garver{at}gsk.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.